Back to Search
RICHARD DIASIO, MD
MD
Family Medicine Physician
NPI: 1427058965Individual
Specialties, Licenses & Credentials
Family Medicine PhysicianPrimary
Family Medicine
Code: 207Q00000X
CL 21153(CO)
Research & Publications (20)
Targeting the epidermal growth factor receptor in the treatment of colorectal cancer: state of the art.
PMID 16906777·Drugs·2006
6-review
Current status of oral chemotherapy for colorectal cancer.
PMID 11301835·Oncology (Williston Park)·2001
6-review
Clinical implications of dihydropyrimidine dehydrogenase on 5-FU pharmacology.
PMID 11219973·Oncology (Williston Park)·2001
6-review
The role of pharmacogenetics and pharmacogenomics in cancer chemotherapy with 5-fluorouracil.
PMID 10971206·Pharmacology·2000
6-review
Prognostication of pancreatic adenocarcinoma by expression of thymidine phosphorylase/dihydropyrimidine dehydrogenase ratio and its correlation with survival.
PMID 19663627·Expert Opin Drug Saf·2009
8-other
Capecitabine-related cardiotoxicity: recognition and management.
PMID 18257400·J Support Oncol·2008
8-other
Atypical toxicity associated with 5-Fluororacil in a DPD-deficient patient with pancreatic cancer. Is ethnicity a risk factor?
PMID 18326935·JOP·2008
5-case
Genetic regulation of beta-ureidopropionase and its possible implication in altered uracil catabolism.
PMID 18216719·Pharmacogenet Genomics·2008
8-other
Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.
PMID 18245778·Ann Oncol·2008
4-observational
Priorities in colorectal cancer research: recommendations from the Gastrointestinal Scientific Leadership Council of the Coalition of Cancer Cooperative Groups.
PMID 17538178·J Clin Oncol·2007
6-review
Hypokalemia secondary to capecitabine: a hidden toxicity?
PMID 18360625·Ther Clin Risk Manag·2007
8-other
Suppression of DPYD expression in RKO cells via DNA methylation in the regulatory region of the DPYD promoter: a potentially important epigenetic mechanism regulating DPYD expression.
PMID 17612628·Biochem Cell Biol·2007
8-other
Long-term survival on capecitabine in two gemcitabine refractory pancreatic cancer patients. Is there a pharmacogenetic explanation?
PMID 17993734·JOP·2007
5-case
Genetic regulation of dihydropyrimidinase and its possible implication in altered uracil catabolism.
PMID 18075467·Pharmacogenet Genomics·2007
8-other
Palmar-plantar erythrodysesthesia in patients receiving capecitabine and intratumor thymidine phosphorylase and dihydropyrimidine dehydrogenase: is there a pharmacologic explanation?
PMID 18632519·Support Cancer Ther·2007
8-other
DIHYDROPYRIMIDINE DEHYDROGENASE DEFICIENCY (DPD) IN GI MALIGNANCIES: EXPERIENCE OF 4-YEARS.
PMID 18846242·Pak J Med Sci·2007
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 625 N CASCADE AVE, SUITE 215
COLORADO SPRINGS, CO 80903 - Phone
- (719) 633-2181
Quick Facts
- NPI
- 1427058965
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile